On July 19, 2022, the DPH shared updated clinical guidance for COVID-19 therapeutics. Nirmatrelvir/ritonavir (PAXLOVID) continues to be the preferred treatment for most patients with mild-to-moderate COVID-19 at high risk of progression to severe disease and continues to be widely available and in adequate supply in Massachusetts.
Updates include:
- Post-treatment COVID-19 rebound has been observed in a small subset of patients that have received nirmatrelvir/ritonavir (PAXLOVID).
- Nirmatrelvir/ritonavir (PAXLOVID) may be prescribed by state-licensed pharmacists under specific conditions outlined in the Emergency Use Authorization.
- Repeat dosing of tixagevimab/cilgavimab (EVUSHELD) is recommended every six months.